Cutaneous manifestations in inflammatory bowel disease (Review)

• Published in: Experimental and therapeutic medicine Vol. 20; no. 1; pp. 31 - 37
• Main Authors: Ungureanu, Loredana, Cosgarea, Rodica, Badea, Mihail Alexandru, Vasilovici, Alina Florentina, Cosgarea, Ioana, Senila, Simona Corina
• Format: Journal Article
• Language: English
• Published: Athens Spandidos Publications 01.07.2020; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Abscesses; Adalimumab; Care and treatment; Complications and side effects; Crohns disease; Cutaneous manifestations of general diseases; Dermatologic agents; Development and progression; Gastrointestinal diseases; Gastrointestinal system; Health screening; Inflammation; Inflammatory bowel disease; Inflammatory bowel diseases; Medical research; Metastasis; Ostomy; Review; Skin; Systemic diseases; Romania
• ISSN: 1792-0981; 1792-1015
• DOI: 10.3892/etm.2019.8321

Inflammatory bowel disease (IBD) is defined as a chronic condition characterized by unpredictable relapsing episodes of gastrointestinal inflammation. IBD is not limited to the gastrointestinal tract and should be considered a systemic disease which can involve any organ. Cutaneous manifestations in IBD are frequent and comprise a broad spectrum of diseases, ranging from mild to severe and sometimes debilitating lesions. Some of the cutaneous manifestations can present signs of an underlying intestinal disease, leading to the screening for non-detected IBD even in the absence of symptoms. Cutaneous EIMs are divided into 4 categories: i) Disease-specific lesions that show the same histopathologic findings as the underlying gastrointestinal disease, ii) reactive lesions which are inflammatory lesions that share a common pathogenetic mechanism but do not share the same pathology with the gastrointestinal disease, iii) associated conditions are more frequently observed in the context of IBD, without sharing the pathogenetic mechanism or the histopathological findings with the underlying disease and iv) drug-related skin reactions.